Ann: Race starts preclinical breast cancer study for Bisantrene, page-59

Hahaha. That's alright, mate. Only playing.

The most obvious thing to ponder over is whether a low dose of Zantrene synergises with Herceptin (a HER-2 monoclonal) through inhibition of FTO. While that certainly is important, something else that hasn't really been discussed here is whether that same low dose of Zantrene could reverse, reduce, or prevent the cardiotoxicity associated with Herceptin use through upregulation of autophagy in non-cancerous cardiac cells.

How long have researchers tried and failed to reduce or prevent the cardiotoxicity associated with common chemotherapeutics?

Just food for thought.